United Therapeutics [UTHR] vs Zoetis [ZTS] Detailed Stock Comparison

United Therapeutics Corporation

NASDAQ
Loading...

Zoetis Inc.

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: United Therapeutics Corporation wins in 12 metrics, Zoetis Inc. wins in 8 metrics, with 0 ties. United Therapeutics Corporation appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric United Therapeutics Corporation Zoetis Inc. Better
P/E Ratio (TTM) 20.60 19.58 Zoetis Inc.
Price-to-Book Ratio 3.53 15.04 United Therapeutics Corporation
Debt-to-Equity Ratio 0.53 279.59 United Therapeutics Corporation
PEG Ratio 0.83 2.81 United Therapeutics Corporation
EV/EBITDA 13.90 13.96 United Therapeutics Corporation
Profit Margin (TTM) 41.94% 28.24% United Therapeutics Corporation
Operating Margin (TTM) 45.23% 34.69% United Therapeutics Corporation
EBITDA Margin (TTM) 45.23% 34.69% United Therapeutics Corporation
Return on Equity 19.72% 65.99% Zoetis Inc.
Return on Assets (TTM) 12.44% 15.26% Zoetis Inc.
Free Cash Flow (TTM) $1.04B $2.28B Zoetis Inc.
Dividend Yield N/A 1.21% N/A
1-Year Return 74.63% -53.93% United Therapeutics Corporation
Price-to-Sales Ratio (TTM) 7.91 5.26 Zoetis Inc.
Enterprise Value $22.28B $56.75B Zoetis Inc.
EV/Revenue Ratio 7.00 6.00 Zoetis Inc.
Gross Profit Margin (TTM) 86.91% 70.17% United Therapeutics Corporation
Revenue per Share (TTM) $72 $21 United Therapeutics Corporation
Earnings per Share (Diluted) $27.88 $6.02 United Therapeutics Corporation
Beta (Stock Volatility) 0.75 0.97 United Therapeutics Corporation
Short % of Float 8.58% 4.06% Zoetis Inc.

United Therapeutics Corporation vs Zoetis Inc. Stock Performance Analysis

Loading Price Chart...

UTHR
ZTS

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
United Therapeutics Corporation1.74%-6.64%-7.08%5.10%13.90%8.72%
Zoetis Inc.1.51%-4.46%-31.75%-39.76%-38.95%-38.30%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
United Therapeutics Corporation74.63%156.34%216.46%378.74%788.07%2,079.33%
Zoetis Inc.-53.93%-54.80%-55.66%62.09%150.53%150.53%

Performance & Financial Health Analysis: United Therapeutics Corporation vs Zoetis Inc.

MetricUTHRZTS
Market Information
Market Cap i$25.11B$49.75B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i464,4642,727,710
90 Day Avg. Volume i635,8913,835,940
Last Close$549.47$167.10
52 Week Range$272.12 - $609.35$139.70 - $200.33
% from 52W High-9.83%-16.59%
All-Time High$609.35 (May 06, 2026)$249.27 (Dec 27, 2021)
% from All-Time High-9.83%-32.96%
Growth Metrics
Quarterly Revenue Growth0.07%0.03%
Quarterly Earnings Growth0.21%0.04%
Financial Health
Profit Margin (TTM) i0.42%0.28%
Operating Margin (TTM) i0.45%0.35%
Return on Equity (TTM) i0.20%0.66%
Debt to Equity (MRQ) i0.53279.59
Cash & Liquidity
Book Value per Share (MRQ)$162.60$7.84
Cash per Share (MRQ)$66.63$5.48
Operating Cash Flow (TTM) i$1.56B$2.90B
Levered Free Cash Flow (TTM) i$583.20M$1.79B
Dividends
Last 12-Month Dividend Yield iN/A1.21%
Last 12-Month Dividend iN/A$2.03

Valuation & Enterprise Metrics Analysis: United Therapeutics Corporation vs Zoetis Inc.

MetricUTHR (Apr 24, 2026)ZTS (Apr 13, 2026)
Price Ratios
P/E Ratio (TTM) i20.6019.58
Forward P/E i16.8715.61
PEG Ratio i0.832.81
Price to Sales (TTM) i7.915.26
Price to Book (MRQ) i3.5315.04
Market Capitalization
Market Capitalization i$25.11B$49.75B
Enterprise Value i$22.28B$56.75B
Enterprise Value Metrics
Enterprise to Revenue i7.006.00
Enterprise to EBITDA i13.9013.96
Risk & Other Metrics
Beta i0.750.97
Book Value per Share (MRQ) i$162.60$7.84

Financial Statements Comparison: United Therapeutics Corporation vs Zoetis Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricUTHR (2025)ZTS (2025)
Revenue/Sales i3.18B9.47B
Cost of Goods Sold i384.40M2.67B
COGS % of Revenue i12.1%28.2%
Gross Profit i2.80B6.80B
Gross Margin i87.9%71.8%
Research & Development i550.00M698.00M
Operating Income (EBIT) i1.52B3.60B
Operating Margin i47.7%38.0%
EBITDA i1.84B4.17B
EBITDA Margin i57.9%44.1%
Pre-Tax Income i1.71B3.36B
Pre-Tax Income % of Revenue i53.9%35.5%
Income Tax i379.20M687.00M
Income Tax % of Revenue i11.9%7.3%
Net Income (Profit) i1.33B2.67B
Profit Margin i41.9%28.2%

Balance Sheet & Liquidity Metrics

MetricUTHR (2025)ZTS (2025)
Cash & Equivalents i1.56B2.31B
Total Current Assets i3.70B6.77B
Total Current Assets % of Revenue i116.3%71.5%
Total Current Liabilities i560.60M2.24B
Total Current Liabilities % of Revenue i17.6%23.6%
Long-Term Debt iN/A9.24B
Long-Term Debt % of Revenue i0.0%97.6%
Total Shareholders Equity i7.10B3.33B
Retained Earnings i8.56B13.74B
Retained Earnings % of Revenue i268.9%145.2%
Property, Plant & Equipment i0288.00M

Cash Flow Statement Comparison

MetricUTHR (2025)ZTS (2025)
Operating Cash Flow i1.44B2.78B
Operating Cash Flow % of Revenue i45.3%29.3%
Capital Expenditures i-520.50MN/A
Free Cash Flow i1.04B2.28B
FCF Margin i32.5%24.1%
Debt Repayment i-500.00M-1.35B
Common Stock Repurchase i-1.02B-3.24B

Short Interest & Institutional Ownership Analysis

MetricUTHRZTS
Shares Short i2.84M15.12M
Short Ratio i4.403.60
Short % of Float i8.58%4.06%
Shares Outstanding i43.64M424.93M
Float Shares i40.32M421.29M
% Held by Insiders i1.94%0.15%
% Held by Institutions i97.78%101.50%
% Held by Public i0.28%-1.65%

Dividend Analysis & Yield Comparison: United Therapeutics Corporation vs Zoetis Inc.

MetricUTHRZTS
Last 12-Month Dividend iN/A$2.03
Last 12-Month Dividend Yield iN/A1.21%
3-Year Avg Annual Dividend iN/A$1.80
3-Year Avg Dividend Yield iN/A0.29%
3-Year Total Dividends iN/A$5.39
Ex-Dividend DateN/AJan 20, 2026